Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fibrillation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed Wolff-Parkinson-White syndrome treadted with digoxin - Mulla N et al. - 1995 (Pediatr. Emerg. Care, 11 (4) 238-239)Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed Wolff-Parkinson-White syndrome treadted with digoxin - Mulla N et al. - 1995 (Pediatr. Emerg. Care, 11 (4) 238-239)
    Active substance: ADENOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 46305
    Study title: "Restoration of sinus rhythm in patients with atrial fibrillation. - Talajic M et al. - 1996 (Can. J. Cardiol., 12: 29A-35A) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" "Restoration of sinus rhythm in patients with atrial fibrillation. - Talajic M et al. - 1996 (Can. J. Cardiol., 12: 29A-35A) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45157
    Study title: "Ventricular fibrillation in two infants treated with amiodarone hydrochloride. - Pohlgeers A, et al. - 1995 (Ped. Cardiol., 16 (2): 82-84) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" "Ventricular fibrillation in two infants treated with amiodarone hydrochloride. - Pohlgeers A, et al. - 1995 (Ped. Cardiol., 16 (2): 82-84) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45149
    Study title: "Conversion of recent-onset atrial fibrillation with intravenous amiodarone: meta-analysis of randomised controlled trials. - Hilleman DE et al. - 2002 (Pharmacother., 22 (1): 66-74) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES " "Conversion of recent-onset atrial fibrillation with intravenous amiodarone: meta-analysis of randomised controlled trials. - Hilleman DE et al. - 2002 (Pharmacother., 22 (1): 66-74) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES "
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45197
    Study title: "Pharmacologic management of supraventicular tachycardias in children - Part 2 : atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. - Luedtke SA et al. - 1997 (Ann. Pharmacother; 31:1347-1359) ; - Publication in CES EXPCRC-" "Pharmacologic management of supraventicular tachycardias in children - Part 2 : atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. - Luedtke SA et al. - 1997 (Ann. Pharmacother; 31:1347-1359) ; - Publication in CES EXPCRC-"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45153
    Study title: Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.Fetsch T, Bauer P, Engberding R, Koch−Hans P, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe−Hans J, Treese N , Breithardt G. European heart journal, Aug 2004, vol. 25, no. 16, p. 1385−94, Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.Fetsch T, Bauer P, Engberding R, Koch−Hans P, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe−Hans J, Treese N , Breithardt G. European heart journal, Aug 2004, vol. 25, no. 16, p. 1385−94,
    Active substance: VERAPAMIL
    Study summary document link (including results):
    View full study record
    Document reference: 45536
    Study title: Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).De Simone A, De Pasquale M, De Matteis C, Canciello M, Manzo M, Sabino L, Alfano F, Di− Mauro M, Campana A, De−Fabrizio G, Vitale DF, Turco P, Stabile−G. European heart journal, Aug 2003, vol. 24, no. 15, p. 1425−9, Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).De Simone A, De Pasquale M, De Matteis C, Canciello M, Manzo M, Sabino L, Alfano F, Di− Mauro M, Campana A, De−Fabrizio G, Vitale DF, Turco P, Stabile−G. European heart journal, Aug 2003, vol. 24, no. 15, p. 1425−9,
    Active substance: VERAPAMIL
    Study summary document link (including results):
    View full study record
    Document reference: 45537
    Study title: Zur antiarrhythmischen Wirksamkeit von Disopyramid bei ventrikulärer Extrasystolie und Vorhofflimmern. (Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation).Breithardt G, Haerten K, Seipel L. Zeitschrift für Kardiologie, Aug 1976, vol. 65, no. 8, p. 713−23,Zur antiarrhythmischen Wirksamkeit von Disopyramid bei ventrikulärer Extrasystolie und Vorhofflimmern. (Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation).Breithardt G, Haerten K, Seipel L. Zeitschrift für Kardiologie, Aug 1976, vol. 65, no. 8, p. 713−23,
    Active substance: VERAPAMIL
    Study summary document link (including results):
    View full study record
    Document reference: 45565
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:54:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA